About Holy Name Medical Center
List of Clinical Studies |
|
| Gynecologic Oncology - Cervical Cancer | |
| Study Name | Principal Investigator |
 |
|
|
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer. Hypothesis is that addition of Pembrolizumab lengthens progression-free survival and overall-survival. Read more. |
Sharyn Lewin, MD Maria Schiavone, MD |
|
|
|
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer. Hypothesis is that addition of Pembrolizumab lengthens progression-free survival and overall-survival. Read more. |
Sharyn Lewin, MD |
|
|
| Gynecologic Oncology - Endometrial Cancer | |
| Study Name | Principal Investigator |
|
|
|
A Multicenter, Open-label, Randomized Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab versus Treatment of Physician's Choice in Participants with Advanced Endometrial Cancer. Hypothesis is that combination therapy leads to improved progression-free survival. Read more. |
Sharyn Lewin, MD Maria Schiavone, MD |
|
|
|
A Phase 3 Randomized, Open-label, Study of Pembrolizumab (MK-3475) Plus Levantinib versus Chemotherapy for First-Line Treatment of Advanced or Recurrent Endometrial Carcinoma. Hypothesis is that the combination for pembrolizumab plus Levantinib is superior to chemotherapy with respect to progression-free survival. Read more. |
Sharyn Lewin, MD Maria Schiavone, MD |
|
|
|
A Multicenter, Open-label, Randomized Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab versus Treatment of Physician’s Choice in Participants with Advanced Endometrial Cancer. Hypothesis is that combination therapy leads to improved progression-free survival. Read more. |
Sharyn Lewin, MD |
|
|
|
A Phase 3 Randomized, Open-label, Study of Pembrolizumab (MK-3475) Plus Levantinib versus Chemotherapy for First-Line Treatment of Advanced or Recurrent Endometrial Carcinoma. Hypothesis is that the combination for pembrolizumab plus Levantinib is superior to chemotherapy with respect to progression-free survival. Read more. |
Sharyn Lewin, MD |
|
|
| Gynecologic Oncology - Mixed Cancer Indication | |
| Study Name | Principal Investigator |
|
|
|
A Phase III, Multicenter, Randomized Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin and Bevacizumab for Patients with Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube or Primary peritoneal Cancer. Hypothesis is that addition of Atezolizumab prolongs progression-free survival. Read more. |
Sharyn Lewin, MD Maria Schiavone, MD |
|
|
|
A Phase III, Multicenter, Randomized Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin and Bevacizumab for Patients with Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube or Primary peritoneal Cancer. Hypothesis is that addition of Atezolizumab prolongs progression-free survival. Read more. |
Sharyn Lewin, MD |
|
|
|
Non-Randomized, Open label Phase II Study to Assess Olaparib tablets as a treatment for Subjects with Different HRD Tumor status and with Platinum -Sensitive, Relapsed, High Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that have received at least 1 Line of chemotherapy. Read more. |
Sharyn Lewin, MD |
|
|
| Gynecologic Oncology - Ovarian Cancer | |
| Study Name | Principal Investigator |
|
|
|
A Randomized, double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer. Hypothesis is that TSR-042 and Niraparib produces a deeper response and prolonged progression-free survival. Read more. |
Sharyn Lewin, MD Maria Schiavone, MD |
|
|
|
A Randomized, double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer. Hypothesis is that TSR-042 and Niraparib produces a deeper response and prolonged progression-free survival. Read more. |
Sharyn Lewin, MD |
|
|